Payment overview · 2025
General Payments
$2,737.59
144 reported records · 14 companies
Healthcare provider profile · identity verified
Antonio Eugenio Tauler, MD
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Psychiatry · CORAL GABLES, FL · NPI 1851342844
Verified facts
What the public records show
CMS Open Payments records show Antonio Eugenio Tauler, MD received $2,737.59 in general payments during 2025 across 144 reported records.
E.R. Squibb & Sons, L.L.C. accounted for 15.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Austedo Xr, Rexulti, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VIIBRYD as an associated drug or biological on 57 records involving 55 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Viibryd by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 161 claims for Vraylar by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 143 claims for Rexulti by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 143 claims for Rexulti by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO XR as an associated drug or biological on 86263 records involving 23643 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Austedo Xr by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $421.06 | 15.4% | 16 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $355.78 | 13.0% | 24 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $331.17 | 12.1% | 15 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $289.99 | 10.6% | 18 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $261.03 | 9.5% | 14 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $251.99 | 9.2% | 14 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $249.23 | 9.1% | 11 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $169.83 | 6.2% | 12 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $151.73 | 5.5% | 8 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $135.04 | 4.9% | 7 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $48.60 | 1.8% | 2 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $26.50 | 1.0% | 1 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $25.31 | 0.9% | 1 | 2025 |
| Luye Pharma (USA) Ltd. | Unresolved — no canonical attribution shown | $20.33 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,626.10 | 143 |
| Education | $111.49 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $421.06 | 16 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $380.30 | 21 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $355.78 | 24 | 2025 |
Source payment records
|
|||||
| INVEGA SUSTENNA Normalized: invega sustenna |
Drug | Janssen Pharmaceuticals, Inc | $289.99 | 18 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $249.23 | 11 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $196.78 | 13 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $151.73 | 8 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $144.08 | 11 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $144.08 | 11 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $135.04 | 7 | 2025 |
Source payment records
|
|||||
| ABILIFY ASIMTUFII Normalized: abilify asimtufii |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $132.72 | 7 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $56.89 | 3 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $48.60 | 2 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $26.50 | 1 | 2025 |
Source payment records
|
|||||
| VIVITROL Normalized: vivitrol |
Drug | Alkermes, Inc. | $25.75 | 1 | 2025 |
Source payment records
|
|||||
| TONMYA Normalized: tonmya |
Drug | Tonix Medicines, Inc. | $25.31 | 1 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $22.90 | 1 | 2025 |
Source payment records
|
|||||
| ERZOFRI EXTENDED-RELEASE Normalized: erzofri extended release |
Drug | Luye Pharma (USA) Ltd. | $20.33 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AUSTEDO XR austedo xr |
2025 | Austedo Xr | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 143 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 161 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VIIBRYD open payments reported associated product |
CMS Open Payments — General Payments 57 supporting records · 55 recipient NPIs · example record 1201398050 |
Viibryd · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
161 | 21 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
143 | 20 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
143 | 20 |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO XR open payments reported associated product |
CMS Open Payments — General Payments 86263 supporting records · 23643 recipient NPIs · example record 1247244228 |
Austedo Xr · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Clonazepam | Clonazepam | 1490 | 211 |
| Trazodone Hcl | Trazodone Hcl | 971 | 166 |
| Alprazolam | Alprazolam | 964 | 120 |
| Fluoxetine Hcl | Fluoxetine Hcl | 705 | 103 |
| Quetiapine Fumarate | Quetiapine Fumarate | 682 | 99 |
| Escitalopram Oxalate | Escitalopram Oxalate | 659 | 110 |
| Mirtazapine | Mirtazapine | 653 | 119 |
| Risperidone | Risperidone | 585 | 82 |
| Sertraline Hcl | Sertraline Hcl | 564 | 87 |
| Aripiprazole | Aripiprazole | 505 | 89 |
| Duloxetine Hcl | Duloxetine Hcl | 504 | 82 |
| Bupropion Xl | Bupropion Hcl | 402 | 67 |
| Lorazepam | Lorazepam | 389 | 57 |
| Buspirone Hcl | Buspirone Hcl | 299 | 58 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 299 | 54 |
| Olanzapine | Olanzapine | 275 | 44 |
| Benztropine Mesylate | Benztropine Mesylate | 261 | 43 |
| Donepezil Hcl | Donepezil Hcl | 231 | 38 |
| Paroxetine Hcl | Paroxetine Hcl | 180 | 34 |
| Temazepam | Temazepam | 168 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 165 | 26 |
| Vraylar | Cariprazine Hcl | 161 | 21 |
| Rexulti | Brexpiprazole | 143 | 20 |
| Memantine Hcl | Memantine Hcl | 110 | 22 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 107 | 18 |
| Lamotrigine | Lamotrigine | 101 | 13 |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 94 | 13 |
| Clozapine | Clozapine | 91 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 81 | 12 |
| Lurasidone Hcl | Lurasidone Hcl | 78 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 69 | 11 |
| Divalproex Sodium | Divalproex Sodium | 68 | 16 |
| Vilazodone Hcl | Vilazodone Hcl | 65 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 54 | suppressed |
| Perphenazine | Perphenazine | 49 | suppressed |
| Haloperidol | Haloperidol | 47 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 46 | 11 |
| Divalproex Sodium Er | Divalproex Sodium | 44 | suppressed |
| Trifluoperazine Hcl | Trifluoperazine Hcl | 43 | suppressed |
| Chlordiazepoxide Hcl | Chlordiazepoxide Hcl | 36 | suppressed |
| Gabapentin | Gabapentin | 34 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 30 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 30 | suppressed |
| Belsomra | Suvorexant | 27 | suppressed |
| Rivastigmine | Rivastigmine | 26 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 21 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Diazepam | Diazepam | 20 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 18 | suppressed |
| Austedo Xr | Deutetrabenazine | 17 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 14 | suppressed |
| Viibryd | Vilazodone Hcl | 13 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 11 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 11 | suppressed |
| Risperdal Consta | Risperidone Microspheres | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,737.59 · 144 records | E.R. Squibb & Sons, L.L.C. | ABILIFY ASIMTUFII, ARISTADA, AUSTEDO XR, Auvelity, CAPLYTA, COBENFY, ERZOFRI EXTENDED-RELEASE, FANAPT, HETLIOZ, INGREZZA, INVEGA SUSTENNA, LOREEV XR, LYBALVI, REXULTI, TONMYA, UZEDY, VIVITROL, VRAYLAR | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Austedo Xr play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error